Terns Pharmaceuticals (TERN)

Overall impact
B (69)

Commentary

Terns Pharmaceuticals is a strong overall performer. With a 'B' rating of 68.8 for overall impact (80th percentile compared to all companies), Terns Pharmaceuticals ranks 312th out of 653 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 308 others, and ahead of Viking Therapeutics, Kadmon, Madrigal Pharmaceuticals and 338 others. On top material causes for Terns Pharmaceuticals's industry (Biotechnology), Terns Pharmaceuticals performs well in Child and Maternal Health (95.4 score), Disease Eradication (96.3), Accountable Institutions (84.9) and 13 other causes where it received an 'A' score and performs poorly in Improved Mental Health (28.4 score), Improved Mental Health (28.4), Sustainable Use of Water (16.0) and 5 other causes where it received a 'D' or 'F' score.
Impact
Cause TERN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2016
Employees
66
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
California, United States
Share classes
TERN
Description
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
Material causes
Ethos considers the following causes material for Terns Pharmaceuticals, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.